Acadian Asset Management LLC Buys 20,784 Shares of Illumina, Inc. $ILMN

Acadian Asset Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 171.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,921 shares of the life sciences company’s stock after buying an additional 20,784 shares during the period. Acadian Asset Management LLC’s holdings in Illumina were worth $2,608,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Rise Advisors LLC raised its position in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares during the period. Rakuten Securities Inc. increased its stake in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 270 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in Illumina in the first quarter worth $33,000. Fourth Dimension Wealth LLC acquired a new stake in Illumina in the fourth quarter worth $40,000. Finally, PFS Partners LLC boosted its position in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 400 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $100.92 on Tuesday. The firm has a market cap of $15.51 billion, a P/E ratio of 12.77, a price-to-earnings-growth ratio of 2.14 and a beta of 1.43. The business’s 50 day moving average is $99.53 and its 200-day moving average is $88.61. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the firm posted $0.36 EPS. The company’s revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a research report on Monday, July 28th. Stephens set a $110.00 target price on Illumina and gave the company an “overweight” rating in a research note on Monday, August 4th. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and lowered their price target for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Finally, Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $123.06.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.